ArticleBrain communications2026
Safety, tolerability and preliminary efficacy of ALMB-0166 in patients with acute spine cord injury.
Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ALMB-0166 is a first-in-class humanized monoclonal antibody that blocks connexin-43 hemichannels on spinal cord astrocytes. By reducing astrocyte and microglia activation, attenuating axonal degeneration and preventing the release of ATP, glutamate, ions and other molecules that drive excitotoxicity, inflammation and metabolic stress, ALMB-0166 mitigates secondary injury following spinal cord injury (SCI) and promotes neurological recovery. The objective of this study was to evaluate the safety, tolerability, pharmacokinetics (PKs) and efficacy of ALMB-0166 in patients with acute SCI. Eligible patients had acute SCI at or below the C3 level, with an American Spinal Injury Association Impairment Scale (AIS) grade of B or C, and were randomized within 72 h after injury. Patients received a single intravenous dose of ALMB-0166 (200, 600, 1200, 2400 or 4800 mg) or placebo, along with best supportive care. The primary outcome was safety. Secondary outcomes included PKs, immunogenicity and efficacy. A total of 25 patients with C3-C7 SCI were enrolled, of whom 24 received treatment (17 with ALMB-0166 and 7 with placebo). Treatment-emergent adverse events (TEAEs) occurred in 94.1% (16/17) of patients in the ALMB-0166 group and 100% (7/7) of those in the placebo group. Grade ≥3 TEAEs were reported in 17.6% (3/17) of the ALMB-0166 group and 42.9% (3/7) of the placebo group. Treatment-related AEs (TRAEs) occurred in six patients (35.3%) with ALMB-0166 and two patients (28.6%) with placebo; all TRAEs were Grade 1. No deaths occurred. ALMB-0166 exhibited essentially linear PKs over the dose range of 200-4800 mg, with concentrations increasing gradually from the start of infusion, peaking near the end of infusion, and then declining slowly. Compared with placebo, ALMB-0166 treatment was associated with improvement in motor function, sensory function, AIS and pain. Specifically, two patients in the ALMB-0166 group recovered from AIS Grade C to Grade E, whereas no patient in the placebo group recovered to Grade E. Notably, the 1200 and 2400 mg dose groups showed superior efficacy in sensory and motor measures; pooled data from these two groups showed greater improvements in both sensory and motor scores than those in the placebo group. In conclusion, ALMB-0166 demonstrated a manageable safety profile and improved neurological recovery in patients with acute SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.